Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesPetros Pharmaceuticals Inc

Petros Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.003 USD -0.00 ( 3.23%)
Last update at 2026-11-05T21:00:00Z
VOLUME
87526
Market Cap
0.21M

Momentum Score

…

Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Petros Pharmaceuticals Inc (PTPI) is an OTC Pink–listed small pharmaceutical company with limited public disclosures about its operations and assets. Long-term upside would depend on successful development, regulatory approvals and commercialization or licensing of any development programs, which could support revenue growth if achieved.

Material risks include scarce public information, low liquidity on the Pink market, early-stage development and clinical/regulatory uncertainty, and likely need for dilutive financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
5.11M
Revenue Per Share
0.29
Gross Profit TTM
3.90M
Debt / Equity
-0.99
ROE
-124.40%
Net Debt
-5.14M
ROCE
-161.67%
Diluted EPS TTM
1.25

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -4.50M -14.32M -8.16M -20.04M -8.99M
Net income 1.91M -14.32M -8.16M -27.04M -9.36M
Selling general administrative 4.64M 8.75M 9.31M 12.21M 15.59M
Gross profit 0.00M 3.90M 4.19M 3.70M 6.21M
Reconciled depreciation - 2.94M 3.40M 5.60M 6.88M
Ebit - -13.76M -7.63M -15.85M -18.05M
Ebitda -4.50M -10.81M -4.21M -6.84M -11.17M
Depreciation and amortization - 2.94M 3.42M 9.00M 6.88M
Operating income -4.64M -17.68M -13.62M -15.85M -18.05M
Other operating expenses 4.64M 22.79M 19.44M 21.84M 25.86M
Interest expense - 0.56M 0.54M 0.60M 0.37M
Tax provision 0.00M 0.00M 0.00M - 0.00M
Interest income 0.26M 0.37M 0.30M 0.01M -
Net interest income 0.26M -0.19M -0.25M -0.58M -0.37M
Income tax expense -6413.64M 26782.84M 5651.21M 7.00M 0.37M
Total revenue 0.00M 5.11M 5.82M 5.99M 7.81M
Total operating expenses 4.64M 21.58M 17.81M 19.55M 24.26M
Cost of revenue - 1.21M 1.63M 2.29M 1.60M
Total other income expense net 0.14M 3.36M 5.45M -4.19M 9.06M
Net income from continuing ops -4.50M -14.32M -12.70M -20.04M -8.99M
Net income applicable to common shares - - - - -8.99M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.16M 10.64M 33.80M 32.42M 67.39M
Intangible assets - 3.20M 8.97M 25293.15M 25293.15M
Other current assets 0.03M 0.17M 3.22M 0.80M 1.53M
Total liab 2.29M 18.10M 21.32M 15.72M 31.85M
Total stockholder equity 2.87M -7.47M 12.48M 16.70M 35.54M
Other current liab 0.14M 8.39M 5.73M 4.17M 26.42M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.41M 0.00M 0.00M
Retained earnings -111.29M -113.21M -98.89M -90.73M -70.69M
Other liab - - - - 0.46M
Good will - - -8962.77M -25280.90M -25267.86M
Other assets - 3337.69M - - 11.03M
Cash 5.14M 3.71M 13.34M 9.43M 23.85M
Total current liabilities 2.29M 18.03M 10.77M 7.07M 30.98M
Current deferred revenue 2.07M 1.91M 2.05M - -
Net debt -5.14M 3.68M -5.06M 0.31M -23.44M
Short term debt - 7.31M 1.28M 1.09M -
Short long term debt - 7.25M 1.16M 1.09M -
Short long term debt total - 7.39M 8.28M 9.74M 0.41M
Other stockholder equity 114.16M 105.74M 519.94M 107.43M 106.23M
Property plant equipment - - - 0.40M 0.52M
Total current assets 5.16M 7.29M 20.39M 14.67M 30.54M
Net tangible assets - - - - 10.25M
Short term investments - 3706.26M - - -
Net receivables - 0.42M 2.23M 2.11M 3.06M
Long term debt - - 6.86M 8.39M -
Inventory - 3.00M 1.61M 1.82M 0.52M
Accounts payable 0.08M 2.33M 1.71M 1.81M 4.56M
Accumulated other comprehensive income - - -408.98M - -
Non currrent assets other - 136.54M 4.18M 5.11M 11.03M
Non current assets total 0.00M 3.34M 13.41M 17.75M 36.85M
Capital lease obligations - 0.14M 0.26M 0.26M 0.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.02M 0.00M - 0.00M
Change to liabilities - - - 0.00M -1.05M
Total cashflows from investing activities - -0.02M - - -
Net borrowings 0.00M -0.77M -1.46M -1.62M -7.19M
Total cash from financing activities 8.16M -7.00M 11.54M -1.62M 18.57M
Change to operating activities - - - - -3.67M
Net income 2.47M -14.32M -8.16M -20.04M -8.99M
Change in cash 1.43M -9.63M 3.91M -14.42M 6.71M
Begin period cash flow 3.71M 13.34M 9.43M 23.85M 17.14M
End period cash flow 5.14M 3.71M 13.34M 9.43M 23.85M
Total cash from operating activities -6.73M -2.60M -7.63M -12.80M -11.86M
Issuance of capital stock 8.50M 0.00M 15.00M 0.00M 21.75M
Depreciation - 2.94M 3.42M 5.60M 6.88M
Other cashflows from investing activities - -0.02M - - -
Dividends paid 973.98M 1292.92M 556.73M - -
Change to inventory - 0.31M 0.27M -0.84M 0.41M
Change to account receivables - 1.82M -0.14M 0.52M 2.55M
Sale purchase of stock -0.34M -6.23M -2.00M - -
Other cashflows from financing activities 973.98M 1286.68M 13.00M -0.00M 4.01M
Change to netincome - - - 4.94M -8.00M
Capital expenditures 0.00M 0.02M 0.00M 0.00M 0.00M
Change in working capital -0.66M 4.53M 0.62M -3.30M -1.76M
Stock based compensation 0.30M 0.20M 0.42M 1.20M 1.31M
Other non cash items -8.85M 4.05M -3.92M 3.75M 0.19M
Free cash flow -6.73M -2.63M -7.63M -12.80M -11.86M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PTPI
Petros Pharmaceuticals Inc		 -0.00
3.23%		 0.00 - - 0.51 0.33 1.19 -0.15
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Petros Pharmaceuticals Inc

Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.

1185 Avenue of the Americas, New York, NY, United States, 10036

973 242 0005

https://petrospharma.com

3

Name Title Year Born
Mr. John D. Shulman Exec. Chairman 1963
Mr. Fady Boctor M.B.A. Principal Exec. Officer, Pres & Chief Commercial Officer 1978
Mr. Mitchell S. Arnold M.B.A. VP of Fin. & Chief Accounting Officer 1964
Mr. Robert Weinstein Interim Chief Financial Officer 1960
Mr. Keith F. Lavan Advisor 1964
Mr. John David Shulman Executive Chairman of the Board 1963
Mr. Fady Boctor M.B.A. President & Chief Commercial Officer 1978
Mr. Mitchell S. Arnold M.B.A. VP of Finance & Chief Accounting Officer 1964
Mr. Joshua N. Silverman Executive Chairman of the Board 1970
Mr. Robert Weinstein Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…